The pooled HR for OS was 1.50 (95% CI: 1.11–2.03, with a p-value of 0.009, I2 = 0%), and the HR for AML transformation was 3.12 (95% CI: 1.36–7.11, with a p-value of 0.007, I2 = 0%) for patients with low- or intermediate-1-IPSS risk MDS with SRSF2 mutations, compared to SRSF2-unmutated patients (Fig 4), indicating that SRSF2 mutations predicted an independent unfavorable prognostic impact in terms of both OS and AML transformation. This evidence concerns the gene SRSF2 and acute myeloid leukemia.